BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nuijten MJ, Wittenberg W. Cost effectiveness of palivizumab in Spain: an analysis using observational data. Eur J Health Econ 2010;11:105-15. [PMID: 19967425 DOI: 10.1007/s10198-009-0206-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Hussman JM, Li A, Paes B, Lanctôt KL. A review of cost–effectiveness of palivizumab for respiratory syncytial virus. Expert Review of Pharmacoeconomics & Outcomes Research 2014;12:553-67. [DOI: 10.1586/erp.12.45] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
2 Andabaka T, Nickerson JW, Rojas-reyes MX, Rueda JD, Vrca VB, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children: Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Evid -Based Child Health 2013;8:2243-376. [DOI: 10.1002/ebch.1950] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
3 Murray J, Saxena S, Sharland M. Preventing severe respiratory syncytial virus disease: passive, active immunisation and new antivirals. Arch Dis Child 2014;99:469-73. [PMID: 24464977 DOI: 10.1136/archdischild-2013-303764] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
4 Sanchez-Luna M, Burgos-Pol R, Oyagüez I, Figueras-Aloy J, Sánchez-Solís M, Martinón-Torres F, Carbonell-Estrany X. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain. BMC Infect Dis 2017;17:687. [PMID: 29041909 DOI: 10.1186/s12879-017-2803-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
5 Fernlund E, Eriksson M, Söderholm J, Sunnegårdh J, Naumburg E. Cost-effectiveness of palivizumab in infants with congenital heart disease: a Swedish perspective. J Congenit Heart Dis 2020;4. [DOI: 10.1186/s40949-020-00036-w] [Reference Citation Analysis]
6 Paes BA, Mitchell I, Banerji A, Lanctôt KL, Langley JM. A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice. Can Respir J 2011;18:e10-9. [PMID: 21499597 DOI: 10.1155/2011/493056] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
7 Antepowicz A, Habib O, Kirsebom F, Johansson C, Gill DR, Hyde SC. Lentiviral and AAV-mediated expression of palivizumab offer protection against Respiratory Syncytial Virus infection. Sci Rep 2021;11:15694. [PMID: 34344952 DOI: 10.1038/s41598-021-95150-z] [Reference Citation Analysis]
8 Paes B, Manzoni P. Special populations: Do we need evidence from randomized controlled trials to support the need for respiratory syncytial virus prophylaxis? Early Human Development 2011;87:S55-8. [DOI: 10.1016/j.earlhumdev.2011.01.012] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
9 Burls A, Sandercock J. Decision-making under conditions of uncertainty-what can we learn from palivizumab?: Decision-making under conditions of uncertainty. Acta Paediatrica 2011;100:1302-5. [DOI: 10.1111/j.1651-2227.2011.02426.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
10 Buendía JA, Acuña-Cordero R, Rodriguez-Martinez CE. The cost-utility of early use of high-flow nasal cannula in bronchiolitis. Health Econ Rev 2021;11:41. [PMID: 34709481 DOI: 10.1186/s13561-021-00339-7] [Reference Citation Analysis]
11 Díez-Domingo J, Pérez-Yarza EG, Melero JA, Sánchez-Luna M, Aguilar MD, Blasco AJ, Alfaro N, Lázaro P. Social, economic, and health impact of the respiratory syncytial virus: a systematic search. BMC Infect Dis 2014;14:544. [PMID: 25358423 DOI: 10.1186/s12879-014-0544-x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 6.1] [Reference Citation Analysis]
12 Andabaka T, Nickerson JW, Rojas-Reyes MX, Rueda JD, Bacic Vrca V, Barsic B. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children. Cochrane Database Syst Rev 2013;:CD006602. [PMID: 23633336 DOI: 10.1002/14651858.CD006602.pub4] [Cited by in Crossref: 27] [Cited by in F6Publishing: 51] [Article Influence: 3.0] [Reference Citation Analysis]
13 Lanari M, Vandini S, Arcuri S, Galletti S, Faldella G. The use of humanized monoclonal antibodies for the prevention of respiratory syncytial virus infection. Clin Dev Immunol 2013;2013:359683. [PMID: 23840240 DOI: 10.1155/2013/359683] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
14 Gil-Prieto R, Gonzalez-Escalada A, Marín-García P, Gallardo-Pino C, Gil-de-Miguel A. Respiratory Syncytial Virus Bronchiolitis in Children up to 5 Years of Age in Spain: Epidemiology and Comorbidities: An Observational Study. Medicine (Baltimore) 2015;94:e831. [PMID: 26020386 DOI: 10.1097/MD.0000000000000831] [Cited by in Crossref: 32] [Cited by in F6Publishing: 19] [Article Influence: 4.6] [Reference Citation Analysis]
15 Resch B, Sommer C, Nuijten MJ, Seidinger S, Walter E, Schoellbauer V, Mueller WD. Cost-effectiveness of palivizumab for respiratory syncytial virus infection in high-risk children, based on long-term epidemiologic data from Austria. Pediatr Infect Dis J. 2012;31:e1-e8. [PMID: 21960187 DOI: 10.1097/inf.0b013e318235455b] [Cited by in Crossref: 47] [Cited by in F6Publishing: 18] [Article Influence: 4.7] [Reference Citation Analysis]
16 Abraha HY, Lanctôt KL, Paes B. Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention. Expert Rev Respir Med 2015;9:779-99. [PMID: 26457970 DOI: 10.1586/17476348.2015.1098536] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
17 Ginsberg GM, Somekh E, Schlesinger Y. Should we use Palivizumab immunoprophylaxis for infants against respiratory syncytial virus? - a cost-utility analysis. Isr J Health Policy Res 2018;7:63. [PMID: 30554570 DOI: 10.1186/s13584-018-0258-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
18 Buendía JA, Acuña-Cordero R. The cost-effectiveness of hypertonic saline inhalations for infant bronchiolitis. BMC Health Serv Res 2020;20:1001. [PMID: 33138807 DOI: 10.1186/s12913-020-05814-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]